Product Description
Burixafor is an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation; this may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Burixafor)
Mechanisms of Action: CXCR4 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GPCR Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lymphoma, Non-Hodgkin|Multiple Myeloma
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TG-0054-04 | P2 |
Completed |
Lymphoma, Non-Hodgkin|Multiple Myeloma |
2015-11-01 |
|
| TG-0054-03 | P2 |
Completed |
Lymphoma, Non-Hodgkin|Multiple Myeloma |
2013-07-01 |
|
| TG-0054-02 | P2 |
Completed |
Lymphoma, Non-Hodgkin|Multiple Myeloma |
2011-10-01 |
|
| TG-0054-01 | P1 |
Completed |
Healthy Volunteers |
2009-05-01 |
28% |